Welcome to our dedicated page for HOOKIPA Pharma news (Ticker: HOOK), a resource for investors and traders seeking the latest updates and insights on HOOKIPA Pharma stock.
HOOKIPA Pharma Inc. (symbol: HOOK) is a clinical-stage biopharmaceutical company dedicated to the development of immunotherapeutics aimed at preventing and treating infectious diseases and cancer. Leveraging its proprietary arenavirus platform, HOOKIPA has created VaxWave® and TheraT®, groundbreaking technologies that reprogram and stimulate the immune system.
VaxWave® is a replication-deficient viral vector, while TheraT® is an attenuated replicating vector. Both technologies are designed to induce strong pathogen-neutralizing antibodies and CD8+ T cells. Remarkably, these vectors can be administered repeatedly without losing efficacy. TheraT® has shown the ability to stimulate CD8+ T cell responses to tumor antigens, achieving frequencies and potencies comparable to or surpassing those seen in adoptive T cell therapy.
HOOKIPA's viral vectors are administered systemically and target dendritic cells in vivo, effectively activating the immune system. This capability is particularly beneficial in the field of immuno-oncology, where it allows for the systemic combating of both primary and metastatic solid tumors.
In recent achievements, HOOKIPA has successfully completed a Phase 1 clinical trial, demonstrating the potential and safety of its innovative approaches. The company continues to focus on advancing its pipeline, which includes the development of an arenavirus-based immunotherapy for KRAS mutant cancer and a neoadjuvant HPV16-specific immunotherapy combined with chemotherapy for HPV16-positive oropharyngeal cancer.
As of December 31, 2023, the company maintains a robust financial position. HOOKIPA remains committed to pioneering immune-based treatments that offer hope for patients with infectious diseases and cancer, positioning itself at the forefront of biopharmaceutical innovation.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) reported its Q3 2020 financial results, revealing revenue of $4.0 million, up from $2.0 million in Q3 2019, primarily due to higher collaborations with Gilead. However, R&D expenses increased to $16.0 million from $11.0 million, contributing to a net loss of $13.6 million, compared to $11.4 million in the prior year. The company continues its clinical development, including the HB-201 and HB-202 oncology candidates, and is optimistic about upcoming efficacy data.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced their participation in two virtual investor conferences: the SVB Leerink Oncology 1x1 Day on November 19, 2020, and the Piper Sandler 32nd Annual Virtual Healthcare Conference from November 30 to December 3, 2020. The company is focused on developing a new class of immunotherapeutics using their proprietary arenavirus platform. Their ongoing research includes a Phase 2 clinical trial for a CMV vaccine for kidney transplant patients and collaborations with Gilead Sciences for HIV and Hepatitis B treatments.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) will release its third-quarter financial results for the period ending September 30, 2020, on November 12, 2020, before the market opens. Notably, the company will not hold a conference call for this earnings release, with plans to conduct such calls only alongside its fourth-quarter earnings.
HOOKIPA develops immunotherapeutics utilizing its proprietary arenavirus platform, aiming for innovative treatments in infectious diseases and oncology.
HOOKIPA Pharma has announced the first patient dosed with HB-202, an alternate vector therapy for HPV16+ cancers in its ongoing Phase 1/2 trial. The HB-202/HB-201 regimen aims to enhance immune response, with pre-clinical studies showing a ten-fold increase. This addition could significantly impact treatment options for patients with treatment-refractory HPV16+ cancers. The trial's primary endpoint is safety and tolerability, with preliminary data expected in late 2020 or early 2021.
HOOKIPA Pharma (NASDAQ: HOOK) announced the appointment of Professor Jean-Charles Soria to its Board of Directors. Recognized for his expertise in oncology and immunotherapy, Soria's addition is expected to enhance the scientific diversity of the board and support the company’s expansion of its clinical pipeline. Soria has extensive experience, including leadership roles at Gustave Roussy Cancer Center and AstraZeneca. HOOKIPA is focusing on developing immunotherapeutics targeting infectious diseases and cancers through its proprietary arenavirus platform.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) announces participation in the SVB Leerink’s CybeRx Series: Vaccine Forum on September 23-24, 2020. A fireside chat featuring CEO Joern Aldag and CMO Igor Matushansky will occur on September 23 at 12:00 PM ET. HOOKIPA focuses on developing immunotherapeutics for infectious diseases and cancers using their proprietary arenavirus platform. Their technologies include non-replicating and replicating platforms, with a Phase 2 trial ongoing for a Cytomegalovirus vaccine. They also collaborate with Gilead Sciences for HIV and Hepatitis B research.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) has announced its participation in several virtual investor conferences in September 2020, featuring key presentations. The conferences include the H.C. Wainwright 22nd Annual Global Investment Conference from September 14-16, where HOOKIPA will present on September 14 at 10:30 AM ET. Other notable events include the Morgan Stanley Virtual Global Healthcare Conference and the BofA Global Healthcare Conference. The company specializes in immunotherapeutics targeting infectious diseases and cancers, utilizing its proprietary arenavirus platform.
HOOKIPA Pharma reported its Q2 2020 financial results, highlighting a revenue increase to $6.7 million from $4.1 million year-over-year, mainly due to Gilead collaboration reimbursements. The company’s cash position stood at $93.3 million, down from $113.6 million at the end of 2019. R&D expenses decreased to $11.6 million, while G&A expenses rose slightly to $4.3 million. Net loss improved to $7.1 million compared to $12.1 million in Q2 2019. Notably, interim results for the Phase 2 trial of HB-101 showed positive safety and immunogenicity, with ongoing trials for HB-201 and HB-202 progressing well.
HOOKIPA Pharma (NASDAQ: HOOK) announced positive interim results from its Phase 2 clinical trial of the HB-101 CMV vaccine, aimed at kidney transplant patients. The trial, involving 51 CMV-negative individuals, showed that 84% experienced minimal adverse events, indicating good tolerability. Among participants receiving three doses, 100% mounted CMV-neutralizing antibodies. Furthermore, 100% of those receiving three doses exhibited a cellular immune response. The company plans to release preliminary efficacy data by the end of 2020.
FAQ
What is the current stock price of HOOKIPA Pharma (HOOK)?
What is the market cap of HOOKIPA Pharma (HOOK)?
What does HOOKIPA Pharma Inc. specialize in?
What are VaxWave® and TheraT®?
How do the arenavirus technologies work?
What recent achievements has HOOKIPA made?
How are HOOKIPA's viral vectors administered?
What is the financial condition of the company?
What is the significance of TheraT® in cancer treatment?
Who can be contacted for investor relations?
What are the upcoming projects for HOOKIPA?
What makes HOOKIPA's technologies unique?
